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Cancer related anorexia/cachexia syndrome (CACS)
Anorexia is the loss of desire to eat. Cachexia is manifested as weight 
loss involving both adipose tissue and skeletal muscle. CACS is com-
mon in advanced lung cancer patients and bears a poor prognosis. 
Wasting is not due to malnutrition, which preferentially depletes lipids 
from adipose tissue, but involves a complex disruption of several sys-
tems that also leads to anemia, insulin resistance, immunosuppression, 
and activation of an acute-phase response. A recent study by Acharyya 
et al. shows that soluble factors released from tumors or immune ef-
fector cells and implicated in cachexia can lead to a speciﬁc decrease 
in the levels of the myosin heavy chain, a muscle contractile protein 
[Acharyya 2004, Chamberlain 2004].
Because of the underlying metabolic changes, sufﬁcient energy intake 
cannot compensate for the increased energy expenditure. Hence, enteral 
and total parenteral nutrition do not play a role in treating anorexia 
unless there is an anatomic etiology. Although nutritional counsel-
ing might increase food intake, there is no evidence that it improves 
nutritional status. Exercise is a non-pharmacologic intervention that 
has been shown to increase lean body mass and/or muscle strenght in 
patients with during breast cancer therapy and stemcell transplantation. 
Studies in lung cancer are however lacking. 
Pharmacologic management of CACS includes orexigenic -progesta-
gens, cannabinoids, corticosteroids- antimetabolic and anabolic agents. 
Medroxyprogesteron acetate (MPA) is the most well-studied drug 
and has been shown to stimulate increased food intake signiﬁcantly 
and to reverse fat loss concomitantly [Simons 1998]. The observed 
weight gain appears to be mainly because of increased adipose tissue 
rather than lean body mass [Loprinzi 1993]. A Cochrane meta-analysis 
showed a beneﬁt of MPA compared with placebo, particularly with 
regard to appetite improvement and weight gain in cancer patients [Be-
renstein 2005]. Analysis of quality of life was hampered by clinical and 
statistical heterogeneity. There was insufﬁcient information to deﬁne 
the optimal dose of MPA. A major concern about progestational agents 
is the increased potential for thrombotic events, that is dose related. 
Patients with lung cancer have a very high rate of thromboembolic 
disease and the beneﬁt of MPA should be balanced in the individual 
patient against this risk. Other toxicities included impotence in 26% of 
men, adding to the decreased sex interest already present in a sizable 
number of patients [Hopwood 1995].
Cannabinoids reputedly stimulate appetite, both historically and in 
recent studies of human volunteers and AIDS patients. Two randomized 
studies have investigated the role of cannabinoids in CACS versus pla-
cebo, MPA and a combination of cannabinoids and MPA [Jatoi 2002, 
Strasser 2006]. Cannabinoids did not improve patients’ appetite, QOL 
or survival as compared to placebo and was inferior to MPA. Cannabi-
noids hence do not have a clear role for CACS. 
Corticosteroids clearly improve appetite usually for a short time with-
out associated weight gain. Randomized comparisons with MPA are 
lacking. In addition long term administration results in proximal muscle 
weakness and central adiposity. 
Eicosapentaenoic acid (EPA), an α-3-omega fatty acid, has been pro-
posed to have speciﬁc anticachectic effects. Several randomized studies 
have investigated the role of EPA in CACS versus placebo, MPA and a 
combination of EPA and MPA [Bruera 2003]. Cannabinoids did not im-
prove patients’ appetite, weight or survival as compared to placebo and 
was inferior to MPA. EPA hence does not have a clear role for CACS. 
Anabolic agents have not been well studied in cancer patients. Several 
small studies suggest a beneﬁt of nadrolone in patients with lung 
cancer. Randomized comparisons with MPA or corticosteroids are 
lacking. Extracellular adenosine 5-triphosphate (ATP) is involved 
in the regulation of a variety of biologic processes, including neuro-
transmission, muscle contraction, and liver glucose metabolism, via 
purinergic receptors. In nonrandomized studies involving patients with 
different tumor types including NSCLC, ATP infusion appeared to 
inhibit loss of weight and deterioration of QOL and performance status. 
Agteresch et al. demonstrated in a randomized trial in 58 patients with 
advanced NSCLC, that ATP infusion had beneﬁcial effects on weight, 
muscle strength, and QOL [Agteresch 2000]. Conﬁrmatory evidence is 
awaited.
Cancer related fatigue (CRF)
Cancer-related fatigue is a complex, multidimensional problem that 
results from the cancer itself, the therapies used to treat it and coexist-
ing physical and psychological conditions. Fatigue should be assessed 
in every cancer patient at regular intervals using either a Likert scale 
or a 0-10 point VAS. There are a number of potentially reversible 
causes of CRF that can be corrected or minimized: anemia, metabolic 
or electrolyte disturbances, sleeping disorders, depression, side -effects 
of medication. The most-well studied pharmacologic agent in CRF is 
methylphenidate, which is a mild central nervous system stimulant. Its 
mechanism of action is blockage of presynaptic dopamine reuptake. In 
patients with cancer, methylphenidate has been used to manage opioid-
induced sedation, cognitive failure associated with brain tumors, and 
depression. Methylphenidate is usually administered twice a day, at 
breakfast and lunch, in order to minimize insomnia. However, because 
of its rapid onset of action and short half-life, methylphenidate may 
be effective in relieving fatigue when taken on an as-needed basis 
(patient-controlled) throughout the day. This ﬂexible administration 
regimen may signiﬁcantly improve the patient’s quality of life. After 
a promising phase 2 trial, Bruera et al conducted a randomized trial in 
112 patients using 5 mg of methylphenidate or placebo every 2 hours 
as needed to a maximum of 4 capsules a day [Bruera 2006]. Fatigue 
intensity improved signiﬁcantly on day 8 in both the methylphenidate 
and placebo groups. However, there was no signiﬁcant difference in 
fatigue improvement between groups, as measured with questionnaires 
at day 8. Based on these data, the role of pharmacologic intervention in 
CRF is unclear and warrant additional placebo-controlled trials.
Conclusion
Lung cancer is a common malignancy with a high attrition rate and a 
high symptom burden not only in the end stages of disease but also in 
patients with newly diagnosed cancer. Many of these symptoms are 
complex and multifactorial. Comprehensive symptom management 
must begin at the time of diagnosis and continue throughout the course 
of the disease. Patients with advanced stage disease and limited life 
expectancy have the right for minimal suffering and optimal QOL. 
MTP18-01 Non EGFR, Non Angiogenesis Inhibitors, Wed, Sept 5, 07:00 - 08:00
Novel targets for cancer therapy: looking beyond EGFR and 
angiogenesis
Adjei, Alex A. 
Roswell Park Cancer Institute, Buffalo, NY, USA
Increasing understanding of the molecular mechanisms underlying 
tumor growth, progression, and metastasis over the past decade has 
identiﬁed promising targets for the treatment of tumors, including lung 
cancer. In particular targets in the PI3Kinase-Akt survival pathway 
and the ras-raf-ERK proliferative pathway are of increasing relevance. 
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A number of protein targets in these pathways possess dysregulated 
kinase activity, as a result of oncogenic gene mutation or overexpres-
sion, and play a pivotal role in carcinogenesis. Receptor tyrosine 
kinases with roles in proliferation - insulin-like growth factor-I recep-
tor, c-Met, and RET (rearranged during transfection); and cytoplasmic 
non-receptor kinases involved in proliferation and/or prevention of 
apoptosis - the serine/threonine kinases Raf, MEK, mTOR and Aurora 
kinases, and the tyrosine kinase Src. Met is a receptor tyrosine kinase 
widely expressed in epithelial and endothelial cells. Conversely, its 
cognate ligand HGF, is expressed by cells of the mesenchymal lineage, 
facilitating rigorous regulation of Met kinase activity. Activation and/or 
overexpression of Met have been widely documented as a frequent 
event in all major human tumor types Activating mutations of Met have 
been identiﬁed in hereditary and sporadic papillary renal carcinomas, 
in gastric, hepatocellular, head and neck, and ovarian carcinomas, and 
in small cell lung cancers and gliomas. Moreover, Met and/or HGF are 
commonly overexpressed in carcinomas and other solid tumors, and in 
their metastases. In clinical correlative studies, overexpression and/or 
dysregulation of Met and/or HGF is a negative prognostic indicator in 
patients with bladder, breast, cervical, gastric, head and neck, naso-
pharyngeal, thyroid, liver and lung carcinomas, and in patients with 
multiple myeloma and glioma. Twp inhibitors of MEK kinase, XL880 
and ARQ197 as well as an antibody against HGF, AMG102 have com-
pleted phase I trials and will be discussed. IGF-1R is another attractive 
target with 4 monoclonal antibodies targetin this receptor, IMC-A12, 
AMG 479, CP-751,871 and R1507 in the clinic. MEK inhibitors and 
src kinase inhibitors will also be discussed.
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Objective: T4 non-small cell lung carcinoma (NSCLC) is a particular 
group of locally advanced cancers especially when non associated with 
mediastinal lymph node involvement. During the past two decades, sur-
gical techniques for resecting locally advanced tumors [1-6] have been 
reﬁned, allowing consideration for curative surgical therapy in patients 
who would not previously have been considered operative candidates. 
Surgery on patients after induction therapy poses special perioperative 
risks and technical challenges, however. Also, controversy exists in giv-
ing neoadjuvant treatment for the patients who have locally advanced 
disease without mediastinal lymph node involvement. Patients with T4 
tumors with minimal nodal involvement (N0 or N1 disease) may ben-
eﬁt from surgery because these tumors are often more local-regionally 
than systemically aggressive. Survival rates of up to 30% to 40% have 
been reported for selected T4N0/N1 tumors.
The present report is aimed to assess operative mortality, morbidity, 
and long-term results of patients with surgically resected T4 NSCLC.
Methods: A retrospective analysis of survival characteristics in 271 
patients who underwent resection for T4 tumors between 1981- 2006 
was undertaken in a reference center for thoracic surgery. Patients were 
divided into four subgroups: 126 patients with superior sulcus tumors 
that were resected through anterior transclavicular approach, 92 with 
carinal involvement, 39 with massive superior vena cava (SVC) inva-
sion requiring graft interposition and 14 with the tumor invading medi-
astinum, heart, and great vessels (aorta, and proximal main pulmonary 
vessels). There were 221 (81.5%) men and 50 women with a mean age 
of 56.3 years (range, 31-80 years). Only a total of 75 (27.6%) patients 
underwent induction therapy. Lung resection consisted of 115 right 
pneumonectomies (42.4 %), 19 left pneumonectomies, 111 lobecto-
mies and 26 wedge resections. Among 126 patients with thoracic inlet 
tumors who had resection of lung, chest wall and subclavian vessels, 
35 underwent a combined “en bloc” resection of the ﬁrst thoracic verte-
brae at three or four levels associated with spinal ﬁxation. In the group 
of 39 SVC resections and prosthetic replacement, 17 patients required 
a combined right carinal pneumonectomy. Nine operations were per-
formed under cardiopulmonary bypass (CPB). Resection was complete 
in 249 (92%) patients. The pathologic N statuses were N0 in 114, N1 in 
94, N2 in 39, N3 in 17, and M1 in 7 patients. The histologic type was 
predominantly squamous cell carcinoma (n = 132; 48.7%). 139 (51.2%) 
patients received adjuvant therapy including radiation therapy in 109 
cases. Follow-up was complete for all patients.
Results: Overall thirty day mortality and morbidity rates were 4% and 
35%, respectively. Postoperative death occurred in 6 patients (6.5%) 
with carinal resection, one (0.8 %) with superior sulcus tumors, three 
(7.6 %) with SVC invasion, and one with invasion of the mediastinum 
(7.1 %). In univariate and multivariate analyses, only right pneumonec-
tomy (p=0.01) was associated with high rate of postoperative death. At 
follow-up, 185 patients are dead, whereas 86 patients are alive. Mean 
survival was 28 months. Overall 5-year survival rate was 38.4% (Fig-
ure 1). Survivals according to the four subgroups of T4 category were 
as follows: superior sulcus tumor, 36.6%; carinal involvement, 42.5%; 
SVC invasion, 29.7%; invasion of the mediastinum, 59.3%. Recurrenc-
es were observed in 138 patients of whom 29 were local and 15 were 
both local and systemic and 94 were systemic. By multivariate analysis, 
two factors signiﬁcantly and independently inﬂuenced survival: nodal 
status (N0-N1 vs. N2-3M1; p=0.003; 43% vs. 17.7% at 5 years, respec-
tively, ﬁgure 2), and complete resection (R0 vs. R1; p=0.01; 40.4% vs. 
15, 9%, respectively, ﬁgure 3).
Conclusions: Improved surgical techniques have increased the feasibil-
ity and radicality of extended operations for patients with potentially 
resectable but locally invasive NSCLC. Advances in the periopera-
tive management and postoperative care, along with a careful patient 
selection, will likely make the operative mortality and morbidity less 
prohibitive and a more favorable prognosis. 
It has been well demonstrated that the prognosis after operations for T4 
tumors mainly depends on the N stage and complete resection. Patients 
with N0 or minimal N1 disease and patients with complete resection do 
signiﬁcantly better after radical resection, a ﬁnding that clearly justiﬁes 
operative therapy in these patients. Presence of pN2 disease should 
be considered a potential contraindication to resection of T4 tumors. 
On the other hand, both the technical complexity of the operation and 
its rare occurrence therefore suggest centralization of the procedure 
to departments that express profound and continuous interest in such 
